Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
17.6% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
20
users have followed this narrative
New
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.1% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
17
users have liked this narrative
7
users have commented on this narrative
24
users have followed this narrative
9 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
4.7% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
18
users have liked this narrative
7
users have commented on this narrative
21
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
47.4% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Treace Medical Concepts
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
Aging Population And Obesity Will Transform Foot Surgery
Key Takeaways Accelerated adoption of new systems and a highly skilled sales force could drive rapid revenue and earnings growth beyond the market's expectations. Expanding clinical evidence, demographic trends, and upcoming international launches are set to broaden the patient base and improve pricing power and margin resilience.
View narrative
US$12.00
FV
40.5% undervalued
intrinsic discount
10.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
Rackspace Technology
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Digital Transformation And Cloud Adoption Will Fuel Expansion
Key Takeaways Accelerated growth in recurring revenue and margins is expected from larger contract wins, industry-specific focus, and AI-driven operational efficiencies. Strategic partnerships and proprietary technologies are driving expansion into new markets and enhancing client value, boosting top-line and long-term profitability.
View narrative
US$2.00
FV
43.0% undervalued
intrinsic discount
1.90%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
Kura Oncology
AN
AnalystHighTarget
Consensus Narrative from 11 Analysts
Aging Populations And Precision Medicine Will Widen Oncology Frontiers
Key Takeaways Ziftomenib's potential best-in-class profile and streamlined trial strategy could drive rapid adoption and transform revenue and margin growth in AML. Expanding into solid tumors and chronic diseases diversifies revenue opportunities and positions Kura as a platform company with strong long-term growth prospects.
View narrative
US$40.00
FV
82.4% undervalued
intrinsic discount
159.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
FIP
FTAI Infrastructure
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Rising US Infrastructure Spending Will Transform Freight Networks
Key Takeaways Transformative acquisitions and underestimated project expansions position the company for rapid revenue growth, margin gains, and improving long-term free cash flow. Strategic scale, industry trends, and green infrastructure demand set the stage for dominant market positioning and durable, recurring revenue expansion.
View narrative
US$13.00
FV
65.2% undervalued
intrinsic discount
55.49%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
indie Semiconductor
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
EV And ADAS Adoption Will Expand Sensor Opportunities
Key Takeaways Software licensing and new ADAS products could deliver recurring, high-margin revenue and rapid gross profit growth, surpassing current market expectations. Early moves in photonics, quantum, and new industrial verticals position the company to unlock transformative value across multiple markets beyond automotive.
View narrative
US$7.96
FV
45.7% undervalued
intrinsic discount
29.06%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
DNA
Ginkgo Bioworks Holdings
AN
AnalystHighTarget
Consensus Narrative from 3 Analysts
Automation And AI Expansion Will Advance Lab Markets Despite Risks
Key Takeaways Aggressive cost savings and early investments position Ginkgo for faster profitability, higher margins, and substantial operating leverage as growth areas expand. Commercialized automation platforms and entry into academic consumables market enable diversified, recurring revenue streams, while proprietary data assets unlock high-value AI partnerships.
View narrative
US$16.00
FV
27.6% undervalued
intrinsic discount
-4.18%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
AbCellera Biologics
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
AI Integration And Internal Pipeline Will Accelerate Biologics Growth
Key Takeaways Innovative trial execution, distinctive product features, and AI-driven antibody discovery position AbCellera to quickly gain market share and attract significant partner interest. Efficient R&D investment, advanced manufacturing, and growing internal pipeline set the stage for improved profitability and outsized long-term royalty and milestone revenues.
View narrative
US$16.43
FV
74.6% undervalued
intrinsic discount
95.49%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
Digimarc
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
EU Green Deal And Smart Packaging Will Transform Supply Chains
Key Takeaways Deep industry integration and regulatory shifts are set to drive outsized adoption, recurring revenues, and rapid operating leverage for Digimarc. Unique technology and strategic partnerships position Digimarc as a foundational player in digital authentication, supply chain transparency, and smart packaging innovation.
View narrative
US$30.00
FV
72.9% undervalued
intrinsic discount
-3.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
Riskified
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Global E-Commerce Growth Will Accelerate AI Fraud Prevention
Key Takeaways Expanding product suite, global reach, and regulatory trends position Riskified for accelerating multi-product adoption, sticky contracts, and substantial, recurring profit growth across enterprise clients. Leadership in AI-driven fraud prevention amid growing threat complexity is driving increased demand, market differentiation, and improved pricing power among high-value customers.
View narrative
US$7.90
FV
47.4% undervalued
intrinsic discount
9.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 16 hours ago
author updated this narrative
Value any company in seconds
Popular companies